<DOC>
	<DOCNO>NCT00544960</DOCNO>
	<brief_summary>This double- blind , multicenter , randomize Phase II study evaluate efficacy safety AT-101 combination docetaxel relapsed/refractory non-small cell lung cancer</brief_summary>
	<brief_title>A Randomized Phase 2 Study AT-101 Combination With Docetaxel Relapsed/Refractory Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Further Study Details provide Ascenta .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gossypol acetic acid</mesh_term>
	<mesh_term>Gossypol</mesh_term>
	<criteria>Histologically cytologically confirm Stage IIIb pleural/pericardial effusion Stage IV nonsmall cell lung cancer ( NSCLC ) . Progression disease one prior systemic chemotherapeutic regimen locally advance metastatic NSCLC . ( Systemic therapy give adjuvant setting count patient relapse within 6 month last cycle therapy . ) In addition one prior chemotherapeutic regimen , patient may receive erlotinib set . All patient must measurable disease . No unstable progressive brain metastasis . Patients may receive prior radiation therapy must recover treatmentrelated toxicity . ECOG performance status 01 Adequate hematologic function Adequate liver renal function Ability swallow oral medication Prior chemotherapy regimen contain docetaxel . Active secondary malignancy . Uncontrolled concurrent illness include , limited : serious uncontrolled infection , symptomatic congestive heart failure ( CHF ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Failure recover toxicity relate prior therapy ( e.g. , surgery , radiation , chemotherapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>AT101</keyword>
	<keyword>AT-101</keyword>
	<keyword>cancer</keyword>
	<keyword>lung</keyword>
	<keyword>non-small cell</keyword>
	<keyword>docetaxel</keyword>
	<keyword>bcl</keyword>
</DOC>